-
Featured News /
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Cras lacinia et tellus sit amet porttitor. Proin ante justo, pulvinar nec neque quis, gravida molestie ligula. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed eget elit fermentum orci eleifend varius. Nunc molestie ornare magna at finibus. Donec quis tempus elit. Suspendisse gravida mi non ultricies laoreet. Sed aliquet mi eu dui finibus sagittis. Fusce efficitur eros nec sem auctor, in facilisis sapien consequat. Donec luctus gravida turpis, vel facilisis est lacinia at. Mauris ultricies volutpat lobortis. Suspendisse facilisis, risus convallis suscipit maximus, lectus ligula tincidunt augue, nec placerat purus tellus in mi. Maecenas ut dui non ex feugiat interdum. In egestas pulvinar eros in rhoncus. Aliquam in lacus orci. Sed auctor, purus in porta interdum, sem justo dignissim lorem, at placerat ligula quam ultrices felis.
Phasellus a commodo nisl, vel scelerisque mi. Donec volutpat sapien nisl, eu pulvinar dui placerat ac. Nullam aliquam congue turpis, vel placerat eros. Curabitur ut dolor imperdiet elit placerat blandit. Nullam mi metus, faucibus ac tellus et, elementum placerat erat. Sed ullamcorper lacinia pellentesque. Mauris eget pulvinar sapien. Mauris vitae lectus ac lorem feugiat blandit eu ac purus. Quisque magna elit, suscipit quis mattis ac, feugiat nec mauris. Aliquam mattis diam sit amet ex hendrerit, sit amet aliquet felis molestie. Duis feugiat risus et pellentesque finibus. Cras sollicitudin dolor nec pharetra posuere. Aenean nunc mi, accumsan sed tortor et, maximus tincidunt quam. Duis volutpat nibh in velit rhoncus scelerisque. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Vestibulum ac consequat orci.
-
Featured News /
As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!
-
Featured News /
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.
-
Featured News /
Standing by people with sickle cell disease and their families
-
Featured News /
As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.
-
Featured News /
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
-
Featured News /
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
-
Featured News /
The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.
-
Statement /
-
Featured News /
A recent summit explored how technological advances could impact patient care.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 17
- › Next page